Orphanet: Eenvoudig zoeken

Zoek een klinische studie of trial

Andere zoekoptie(s)

39 Resultaat/Resultaten

Nationale klinische studie(s)

MD-NEt Project R19: Deflazacort in Dysferlinopathies (LGMD2B/MM) - a Double Blind, Placebo-controlled Clinical Study (Phase II-III) - DE Bundesministerium für Bildung und Forschung

Monocentre, prospective, double-blind, placebo-controlled, randomized clinical phase IIa trial to assess the safety, tolerability, and immediate biological effects of Coenzyme Q10 in Progressive Supranuclear Palsy - DE Bundesministerium für Bildung und Forschung

APL-Arsen-Study: Phase IV Safety/Efficacy Study- Treatment Protocol for Relapsed Acute Promyelocytic Leukemia (APL) With Arsenic - DE Bundesministerium für Bildung und Forschung

HD13: Quality assurance protocol to reduce toxicities following first-line therapy for early stage Hodgkin's disease - DE Bundesministerium für Bildung und Forschung

HD14: Quality assurance protocol to improve efficacy of the first-line therapy of intermediate stage Hodgkin's disease - DE Bundesministerium für Bildung und Forschung

HD15: Quality assurance protocol to reduce toxicities and to determine the prognostic significance of FDG-PET imaging in first-line therapy of advanced stage Hodgkin's disease - DE Bundesministerium für Bildung und Forschung

RIPL: Phase-II study: Rituximab, first line therapy for patients with Lymphocyte Predominant Hodgkin´s Disease (LPHD) in clinical stage IA - DE Bundesministerium für Bildung und Forschung

PVAG elderly: Phase I/II Study of Prednisone, Vinblastine, Doxorubicin, and Gemcitabine in Elderly Patients With Advanced Stages Hodgkin's Lymphoma - DE Bundesministerium für Bildung und Forschung

Gene therapy of Wiskott Aldrich Syndrome (Phase I-II) - DE Bundesministerium für Bildung und Forschung

GIMEMA-DSIL APL 0406: A randomised phase III study to compare arsenic trioxide (ATO) combined to ATRA versus standard ATRA and anthracycline-based chemotherapy (AIDA Regimen) for newly diagnosed, non high-risk acute promyelocytic leukaemia -DE Bundesministerium für Bildung und Forschung

Competence Network for Congenital Heart Defects: Carvedilol in the treatment of right ventricular failure in patients with a congenital heart defect (CarveRe-AHF) - DE Bundesministerium für Bildung und Forschung

CARE-CHD : Cardiac resynchronization therapy in heart failure patients with congenital heart defects (Phase II-III) -DE Bundesministerium für Bildung und Forschung

A randomized, double-blind study versus placebo for the evaluation of the efficacy of Doxycycline administered by oral route in patients affected by sporadic Creutzfeldt-Jakob disease (Phase-II study) Bundesministerium für Bildung und Forschung

DMD-Kardio: Effect and Safety of preventive Treatment with ACE-Inhibitor and Beta-Blocker on the onset of Left Ventricular Dysfunction in Duchenne Muscular Dystrophy (Phase III) - DE Bundesministerium für Bildung und Forschung

GLSG Go-Study: Multicentric Phase I/II Study for the efficacy of a combination of Rituximab, Gemcitabine and Oxaliplatin in relapsed/refractory indolent Lymphoma - DE Bundesministerium für Bildung und Forschung

CeTeG: Efficacy and safety study of Lomustine/Temozolomide combination therapy versus standard Temozolomide therapy for newly diagnosed MGMT-methylated Glioblastoma patients (Phase III) -terminated Bundesministerium für Bildung und Forschung

An open label phase II study of the combination of Imatinib and Lonafarnib in patients with CML in chronic phase and absence of good molecular remission - DE Bundesministerium für Bildung und Forschung

AMLSG 15-10: A Randomized phase III study of low-dose Cytarabine and Etoposide with or without All-Trans Retinoic Acid in older patients not eligible for intensive Chemotherapy with Acute Myeloid Leukemia (AML) and NPM1 mutation Bundesministerium für Bildung und Forschung

EARLY PRO-TECT Alport: Prospective, randomised, placebo-controlled, double-blind, industry-independent, multicentre trial of ACE-inhibitor Ramipril versus Placebo in early stages of Alport Syndrome: Optimal Start of Therapy and Safety (Phase III) Bundesministerium für Bildung und Forschung

FIRSTMAPPP study: First international randomised phase II study in malignant progressive Pheochromocytoma and Paraganglioma - DE Bundesministerium für Bildung und Forschung

Clinical effect versus metabolic effect of Estradiol and Testosterone in gonadectomized adult women with 46, XY DSD with Complete Androgen Insensitivity (CAIS): A multicenter, randomized, placebo-controlled, double blind clinical study Bundesministerium für Bildung und Forschung

INTENT Study: Initial treatment of idiopathic nephrotic syndrome in children with mycophenolate mofetil vs. prednisone: A randomized, controlled, multicenter study - DE Bundesministerium für Bildung und Forschung

TAME-AL: A Randomised Trial for the Treatment of Cardiac AMyloid Light-chain (AL) Amyloidosis With the Green Tea Compound Epigallocatechin-3-gallate (Phase II) - DE Bundesministerium für Bildung und Forschung

A randomized, double-blind study to investigate the efficacy and safety of deep brain stimulation of the internal globus pallidus versus Botulinum toxin in patients with Cervical Dystonia - DE Bundesministerium für Bildung und Forschung

NOA-20/Improvement of functional outcome for patients with newly diagnosed grade II or III glioma with co-deletion of 1p/19q - IMPROVE CODEL Bundesministerium für Bildung und Forschung

Phase II trial of vaccination with lysate-loaded, mature dendritic cells integrated into standard radiochemotherapy in newly diagnosed glioblastoma -DE- Bundesministerium für Bildung und Forschung

Effects of Acetyl-DL-Leucine on cerebellar ataxia - a multinational, multicenter, randomized, double-blind, placebo-controlled, 2-way crossover phase III trial (ALCAT) Bundesministerium für Bildung und Forschung

Sequential Optimization of Dose and Schedule of PfSPZ Vaccine, Verified by Randomized, Controlled, Double-blind Immunization and Controlled Human Malaria Infection in Malaria-naïve, Healthy Adult Volunteers in Germany Bundesministerium für Bildung und Forschung

MATRix - IELSG43 : High-dose chemotherapy and autologous stem cell transplant or consolidating conventional chemotherapy in primary CNS lymphoma - randomized phase III trial -DE- Bundesministerium für Bildung und Forschung

ROPROP: Oral Propranolol for prevention of thresholdretinopathy of prematurity - DE Bundesministerium für Bildung und Forschung

MAGE-A1-TCR: A Phase I study with MAGE-A1-specific TCR-altered T cells in patients with relapsed/refractory multiple myeloma Bundesministerium für Bildung und Forschung

Generate-Boost: A Multicenter Randomized, Controlled, Double-blinded Trial to Evaluate Efficacy and Safety of Bortezomib in Patients With Severe Autoimmune Encephalitis (CONNECT-GENERATE study) Bundesministerium für Bildung und Forschung

ABACHAI: Safety and effectiveness of Abatacept (s.c.) in patients with CTLA4 insufficiency or LRBA deficiency (study of the GAIN-Network) Bundesministerium für Bildung und Forschung

SynCoRAS: Improvement of Synaptic Plasticity and Cognitive Function in RAS Pathway Disorders (GeNeRARe study) Bundesministerium für Bildung und Forschung

Clinical trials for Combined Phase 1 and 1/2a Clinical Trial Evaluating the Safety and Efficacy of an Autologous Muscle Stem Cell Therapy in the Treatment of Urinary Incontinence in Isolated Epispadias Bundesministerium für Bildung und Forschung

MecMeth: Phase I/II study of meclofenamate/temozolomide combination therapy for relapsed MGMT promoter-methylated glioblastoma. Bundesministerium für Bildung und Forschung

MD-NEt Project R19: Deflazacort in Dysferlinopathies (LGMD2B/MM) - a Double Blind, Placebo-controlled Clinical Study (Phase II-III) - DE
Bundesministerium für Bildung und Forschung

Monocentre, prospective, double-blind, placebo-controlled, randomized clinical phase IIa trial to assess the safety, tolerability, and immediate biological effects of Coenzyme Q10 in Progressive Supranuclear Palsy - DE
Bundesministerium für Bildung und Forschung

APL-Arsen-Study: Phase IV Safety/Efficacy Study- Treatment Protocol for Relapsed Acute Promyelocytic Leukemia (APL) With Arsenic - DE
Bundesministerium für Bildung und Forschung

HD13: Quality assurance protocol to reduce toxicities following first-line therapy for early stage Hodgkin's disease - DE
Bundesministerium für Bildung und Forschung

HD14: Quality assurance protocol to improve efficacy of the first-line therapy of intermediate stage Hodgkin's disease - DE
Bundesministerium für Bildung und Forschung

HD15: Quality assurance protocol to reduce toxicities and to determine the prognostic significance of FDG-PET imaging in first-line therapy of advanced stage Hodgkin's disease - DE
Bundesministerium für Bildung und Forschung

RIPL: Phase-II study: Rituximab, first line therapy for patients with Lymphocyte Predominant Hodgkin´s Disease (LPHD) in clinical stage IA - DE
Bundesministerium für Bildung und Forschung

PVAG elderly: Phase I/II Study of Prednisone, Vinblastine, Doxorubicin, and Gemcitabine in Elderly Patients With Advanced Stages Hodgkin's Lymphoma - DE
Bundesministerium für Bildung und Forschung

Gene therapy of Wiskott Aldrich Syndrome (Phase I-II) - DE
Bundesministerium für Bildung und Forschung

GIMEMA-DSIL APL 0406: A randomised phase III study to compare arsenic trioxide (ATO) combined to ATRA versus standard ATRA and anthracycline-based chemotherapy (AIDA Regimen) for newly diagnosed, non high-risk acute promyelocytic leukaemia -DE
Bundesministerium für Bildung und Forschung

Competence Network for Congenital Heart Defects: Carvedilol in the treatment of right ventricular failure in patients with a congenital heart defect (CarveRe-AHF) - DE
Bundesministerium für Bildung und Forschung

CARE-CHD : Cardiac resynchronization therapy in heart failure patients with congenital heart defects (Phase II-III) -DE
Bundesministerium für Bildung und Forschung

A randomized, double-blind study versus placebo for the evaluation of the efficacy of Doxycycline administered by oral route in patients affected by sporadic Creutzfeldt-Jakob disease (Phase-II study)
Bundesministerium für Bildung und Forschung

DMD-Kardio: Effect and Safety of preventive Treatment with ACE-Inhibitor and Beta-Blocker on the onset of Left Ventricular Dysfunction in Duchenne Muscular Dystrophy (Phase III) - DE
Bundesministerium für Bildung und Forschung

GLSG Go-Study: Multicentric Phase I/II Study for the efficacy of a combination of Rituximab, Gemcitabine and Oxaliplatin in relapsed/refractory indolent Lymphoma - DE
Bundesministerium für Bildung und Forschung

CeTeG: Efficacy and safety study of Lomustine/Temozolomide combination therapy versus standard Temozolomide therapy for newly diagnosed MGMT-methylated Glioblastoma patients (Phase III) -terminated
Bundesministerium für Bildung und Forschung

An open label phase II study of the combination of Imatinib and Lonafarnib in patients with CML in chronic phase and absence of good molecular remission - DE
Bundesministerium für Bildung und Forschung

AMLSG 15-10: A Randomized phase III study of low-dose Cytarabine and Etoposide with or without All-Trans Retinoic Acid in older patients not eligible for intensive Chemotherapy with Acute Myeloid Leukemia (AML) and NPM1 mutation
Bundesministerium für Bildung und Forschung

EARLY PRO-TECT Alport: Prospective, randomised, placebo-controlled, double-blind, industry-independent, multicentre trial of ACE-inhibitor Ramipril versus Placebo in early stages of Alport Syndrome: Optimal Start of Therapy and Safety (Phase III)
Bundesministerium für Bildung und Forschung

FIRSTMAPPP study: First international randomised phase II study in malignant progressive Pheochromocytoma and Paraganglioma - DE
Bundesministerium für Bildung und Forschung

Clinical effect versus metabolic effect of Estradiol and Testosterone in gonadectomized adult women with 46, XY DSD with Complete Androgen Insensitivity (CAIS): A multicenter, randomized, placebo-controlled, double blind clinical study
Bundesministerium für Bildung und Forschung

INTENT Study: Initial treatment of idiopathic nephrotic syndrome in children with mycophenolate mofetil vs. prednisone: A randomized, controlled, multicenter study - DE
Bundesministerium für Bildung und Forschung

TAME-AL: A Randomised Trial for the Treatment of Cardiac AMyloid Light-chain (AL) Amyloidosis With the Green Tea Compound Epigallocatechin-3-gallate (Phase II) - DE
Bundesministerium für Bildung und Forschung

A randomized, double-blind study to investigate the efficacy and safety of deep brain stimulation of the internal globus pallidus versus Botulinum toxin in patients with Cervical Dystonia - DE
Bundesministerium für Bildung und Forschung

NOA-20/Improvement of functional outcome for patients with newly diagnosed grade II or III glioma with co-deletion of 1p/19q - IMPROVE CODEL
Bundesministerium für Bildung und Forschung

Phase II trial of vaccination with lysate-loaded, mature dendritic cells integrated into standard radiochemotherapy in newly diagnosed glioblastoma -DE-
Bundesministerium für Bildung und Forschung

Effects of Acetyl-DL-Leucine on cerebellar ataxia - a multinational, multicenter, randomized, double-blind, placebo-controlled, 2-way crossover phase III trial (ALCAT)
Bundesministerium für Bildung und Forschung

Sequential Optimization of Dose and Schedule of PfSPZ Vaccine, Verified by Randomized, Controlled, Double-blind Immunization and Controlled Human Malaria Infection in Malaria-naïve, Healthy Adult Volunteers in Germany
Bundesministerium für Bildung und Forschung

MATRix - IELSG43 : High-dose chemotherapy and autologous stem cell transplant or consolidating conventional chemotherapy in primary CNS lymphoma - randomized phase III trial -DE-
Bundesministerium für Bildung und Forschung

ROPROP: Oral Propranolol for prevention of thresholdretinopathy of prematurity - DE
Bundesministerium für Bildung und Forschung

MAGE-A1-TCR: A Phase I study with MAGE-A1-specific TCR-altered T cells in patients with relapsed/refractory multiple myeloma
Bundesministerium für Bildung und Forschung

Generate-Boost: A Multicenter Randomized, Controlled, Double-blinded Trial to Evaluate Efficacy and Safety of Bortezomib in Patients With Severe Autoimmune Encephalitis (CONNECT-GENERATE study)
Bundesministerium für Bildung und Forschung

ABACHAI: Safety and effectiveness of Abatacept (s.c.) in patients with CTLA4 insufficiency or LRBA deficiency (study of the GAIN-Network)
Bundesministerium für Bildung und Forschung

SynCoRAS: Improvement of Synaptic Plasticity and Cognitive Function in RAS Pathway Disorders (GeNeRARe study)
Bundesministerium für Bildung und Forschung

Clinical trials for Combined Phase 1 and 1/2a Clinical Trial Evaluating the Safety and Efficacy of an Autologous Muscle Stem Cell Therapy in the Treatment of Urinary Incontinence in Isolated Epispadias
Bundesministerium für Bildung und Forschung

MecMeth: Phase I/II study of meclofenamate/temozolomide combination therapy for relapsed MGMT promoter-methylated glioblastoma.
Bundesministerium für Bildung und Forschung